Document:

Exhibit 4.8

SPECIMEN UNIT CERTIFICATE

 

	NUMBER

 U-___________	UNITS

 

 

	SEE REVERSE FOR CERTAIN

DEFINITIONS	

 

LIVEDEAL, INC.

CUSIP

UNITS CONSISTING OF [              ] AND [              ]

EACH TO PURCHASE ______________  SHARES OF [              ]

 

	THIS CERTIFIES THAT	

	is the owner of	
	Units.
	 	 	 	 

 Each Unit (“Unit”) consists of _______________
of LIVEDEAL, INC., a Nevada corporation (the “Company”) and ___ Warrant (the “Warrant”). Each [Warrant]
entitles the holder to purchase ____________ for $_______ per share (subject to adjustment). Each [Warrant] will become exercisable
_____________________ (the “Expiration Date”). [The [ ] and [Warrant] comprising the Units represented by this certificate
will trade separately on the ________ trading day following the earlier to occur of ___________________.] The terms of the [Warrant]
are governed by a Warrant Agreement dated as of ____________, between the Company and ________________, as Warrant Agent, and
are subject to the terms and provisions contained therein, all of which terms and provisions the holder of this certificate consents
to by acceptance hereof. Copies of the Warrant Agreement are on file at the office of the Warrant Agent at ________________________,
and are available to any [Warrant] holder on written request and without cost. This certificate is not valid unless countersigned
by the Transfer Agent and Registrar of the Company. 

 

Witness the facsimile seal of the Company and the facsimile
signature of its duly authorized officers.

 

	By	
 

	
 

	 
	 	Chief
    Executive Officer	Secretary

 

LIVEDEAL, INC. CORPORATE

SEAL

1996

NEVADA

 

    	1

    	 

    

 

LIVEDEAL, INC.

 

The Company will furnish without charge
to each stockholder who so requests, a statement of the powers, designations, preferences and relative, participating, optional
or other special rights of each class of stock or series thereof of the Company and the qualifications, limitations, or restrictions
of such preferences and/or rights.

 

The following abbreviations, when used in
the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable
laws or regulations:

 

TEN COM - as tenants in common

TEN ENT - as tenants by the entireties

JT TEN - as joint tenants with
right of survivorship

and not as tenants in common

 

	UNIF GIFT MIN ACT -	
	Custodian	

	 	(Cust)	 	(Minor)
	 	under Uniform Gifts to Minors
	 	Act	

	 	 	(State)
	 	 	 	 	 

 

Additional Abbreviations may also be used though not in the
above list.

 

For value received, ___________________________
hereby sell, assign and transfer unto

 

	PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE	 
	
	 
	
	 
	

                                                                                 

	(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE)
	 	 
	 	 
	
	Units
	represented by the within Certificate, and do hereby irrevocably constitute and appoint
	
	Attorney
	to transfer the said Units on the books of the within named Company will full power of substitution in the premises.
	Dated	
	

	 	 
	 	 	NOTICE:The signature to this assignment must correspond with the name as written upon the face of the certificate in every particular, without alteration or enlargement or any change whatever.
	 
	

	 
	 	 	 	 	 	 

 

 

    	2

    	 

    

Signature(s) Guaranteed:

 

 

	 

THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE
GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE
GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15).

 

    	3Exhibit 10.1

FORM OF 

AMENDMENT TO

AETHLON MEDICAL, INC.

CONVERTIBLE NOTES AND WARRANTS

 

The Convertible Promissory Notes (the “Notes”)
and Common Stock Purchase Warrants (the “Warrants”) set forth on Schedule A hereto, issued by Aethlon Medical,
Inc., a Nevada corporation (the “Company”), to _______________ (the “Holder”), hereby are amended as set
forth herein:

 

The parties hereto agree
as follows:

 

	1.		All defined terms not otherwise defined herein shall have the meanings ascribed to
them in the Notes or Warrants, as applicable.

 

	2.		The term “Maturity Date,” as defined in each of the Notes, shall mean
April 1, 2016.

 

	3.		The non-default rate of interest that shall be payable under each of the Notes shall
be twelve percent (12%) per annum.

 

	4.		The principal amount of each of the Notes shall be increased to the amount calculated
by multiplying (x) the principal amount outstanding immediately prior to the effectiveness of this Amendment by (y) 1.12.

 

	5.		In the event that the Company intends to pay in cash, on or after the Maturity Date
(as redefined in Section 2 above), any amount owing under a Note, the Company shall provide five (5) days’ prior written
notice of such intent (the “Payment Notice”) to the Holder. The Payment Notice shall include proof of funds and confirmation
of the Company’s ability to pay the amount stated in the Payment Notice and shall provide for payment to the Holder, ______________
and ____________________ on a pro rata basis. The Company shall not issue a Payment Notice at any time during which an Event of
Default (as defined in the Notes), other than a failure to pay principal and interest due at the Maturity Date, shall have occurred
and remains outstanding. The Holder shall have the option, exercisable on one occasion by written notice delivered to the Company
within five (5) days after the Holder’s receipt of the Payment Notice, to extend the Maturity Date to the later of (x) July
1, 2016 and (y) the date that is three (3) months following the date of the Holder’s receipt of the Payment Notice. In the
event that the Holder exercises such option, thereafter the Company shall not make any payment on such Note prior to the Maturity
Date, as extended. Further, the Holder’s right to convert the Note, at the Holder’s election, shall continue in full
effect during such extended period.

 

	6.		In connection with any conversions under the Notes effected by the Holder during the
period from October 1, 2011 through the effective date hereof, the Company shall issue to the Holder that number of shares of
the Company’s Common Stock, par value $.001 per share (the “Common Stock”), equal to the difference between
(x) that number of shares of Common Stock that were issued to the Holder upon such conversion and (y) that number of shares of
Common Stock that would have been issuable to the Holder if such conversion had been effected at a conversion price of $.042 per
share. As of the date hereof, in accordance with the foregoing formula, the Holder is entitled to be issued an aggregate of ______________
shares of Common Stock, which shall be issued promptly after execution of this Amendment.

 

    	1

    	 

    

 

	7.		The “Conversion Price,” as defined in each of the Notes, shall be $.042
per share, subject to further adjustment as provided in each such Note.

	 		 

	8.		The “Expiration Date,” as defined in each of the Warrants, shall be January
1, 2017.

	 		 

	9.		The “Purchase Price,” as defined in each of the Warrants, shall be $.042
per share, subject to further adjustment as provided in each such Warrant.

	 		 

	10.		In the event that all outstanding promissory notes and warrants issued by the Company
to the persons listed on Schedule B hereto shall have been amended to remove, or the holders thereof shall have waived,
any provisions contained therein which would act to reduce the conversion or exercise price of such notes or warrants if the Company
were to issue any Common Stock, other than Excepted Issuances (as defined in the subscription agreement under which the applicable
Note or Warrant was purchased), at a price below such conversion or exercise price, then any similar anti-dilution protection
to which the then-outstanding Notes and Warrants are subject shall automatically be deemed removed and, until such Notes and Warrants
are no longer outstanding, the Company shall be prohibited from issuing any Common Stock or securities convertible into or exercisable
for shares of Common Stock (“Common Stock Equivalents”) (or modifying, with equivalent effect, any of the foregoing
that may be outstanding), other than Excepted Issuances, at a price below the Conversion Price of such Notes and Purchase Price
of such Warrants. Other than those issued to the persons listed on Schedule B hereto, there are no other outstanding promissory
notes or warrants or Common Stock Equivalents with provisions that would act to reduce the conversion or exercise price of such
notes or warrants or Common Stock Equivalents if the Company were to issue any Common Stock, other than Excepted Issuances, at
a price below such conversion or exercise price.

	 		 

	11.		The Company represents and warrants that, assuming that all other relevant conditions
to reliance on Rule 144 under the Securities Act of 1933, as amended, have been satisfied, the holding period, for Rule 144 purposes,
of the shares of Common Stock issuable upon conversion of any principal and interest due under the Notes, other than any shares
issuable upon conversion of that portion of the Notes that represents the increase set forth in Section 4 hereof, will tack back
to the original issuance date of the applicable Note and that the holding period, for Rule 144 purposes, of the shares of Common
Stock issuable under Section 6 hereof similarly will tack back to the original issuance date of the applicable Note. The Company
further covenants that it will not take a position contrary to this Section 11 and agrees that taking such contrary position will
be an Event of Default under the Notes.

	 		 

	12.		The effective date of the foregoing amendments to the Notes and the Warrants is March
31, 2014. The Company acknowledges that the Holder has not waived any rights except for those specifically waived herein and that
the Holder reserves all such non-waived rights, including anti-dilution rights and remedies upon the occurrence of an Event of
Default not waived in this Amendment. Except as expressly set forth herein, all other terms of the Notes and the Warrants shall
remain in full force and effect without modification, amendment or restatement.

[Signature page follows]

 

    	2

    	 

    

 

IN WITNESS WHEREOF,
the Company has caused this Amendment to be executed by it duly authorized officer on the 31st day of March, 2014.

 

	 	AETHLON MEDICAL, INC.
	 	 
	 	 
	 	 
	 	By:                                      
	 	James B. Frakes
	 	Chief Financial Officer

 

 

Accepted and agreed to by the Holder:

 

 

 

By: ________________________

Name:________________________

Title:________________________

Address:

 

________________________

________________________

________________________

 

    	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]